EUVIMEDEUVIMED entdecken
Vergleichsstudie

The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology

G Sorce, A Stabile, F Pellegrino, E Mazzone, A Mattei, L Afferi, S Serni, A Minervini, M Roumiguiè, B Malavaud, M Valerio, A Rakauskas und 8 weitere

World Journal of Urology · 2024

DOI: 10.1007/s00345-024-04963-w ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift World Journal of Urology, 2024. Verfasst von G Sorce und 19 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Multiparametric Magnetic Resonance Imaging. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Although targeted biopsies (TBx) are associated with improved disease assessment, concerns have been raised regarding the risk of prostate cancer (PCa) overgrading due to more accurate biopsy core deployment in the index lesion. METHODS: We identified 1672 patients treated with radical prostatectomy (RP) with a positive mpMRI and ISUP ≥ 2 PCa detected via systematic biopsy (SBx) plus TBx. We compared downgrading rates at RP (ISUP 4-5, 3, and 2 at biopsy, to a lower ISUP) for PCa detected via SBx only (group 1), via TBx only (group 2), and eventually for PCa detected with the same ISUP 2-5 at both SBx and TBx (group 3), using multivariable logistic regression models (MVA). RESULTS: Overall, 12 vs 14 vs 6% (n = 176 vs 227 vs 96) downgrading rates were recorded in group 1 vs group 2 vs group 3, respectively (p < 0.001). At MVA, group 2 was more likely to be downgraded (OR 1.26, p = 0.04), as compared to group 1. Conversely, group 3 was less likely to be downgraded at RP (OR 0.42, p < 0.001). CONCLUSIONS: Downgrading rates are highest when PCa is present in TBx only and, especially when the highest grade PCa is diagnosed by TBx cores only. Conversely, downgrading rates are lowest when PCa is identified with the same ISUP through both SBx and TBx. The presence of clinically significant disease at SBx + TBx may indicate a more reliable assessment of the disease at the time of biopsy potentially reducing the risk of downgrading at final pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMultiparametric Magnetic Resonance ImagingHumansMaleMiddle AgedAgedImage-Guided BiopsyNeoplasm GradingProstatectomyRetrospective StudiesRisk AssessmentProstateBiopsy

Stichwörter der Autor:innen

Radical prostatectomySystematic biopsyTargeted biopsympMRI

Autor:innen und Institutionen

  • Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
  • Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy. stabile.armando@hsr.it.
  • Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy. stabile.armando@hsr.it.
  • Klinik Für Urologie, Luzerner Kantonsspital, Luzerner, Switzerland.
  • Department of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy.
  • Department of Urology and Renal Transplantation, Toulouse University Hospital, Toulouse, France.

Zitieren

APA

Sorce, G., Stabile, A., Pellegrino, F., Mazzone, E., Mattei, A., Afferi, L., Serni, S., Minervini, A., Roumiguiè, M., Malavaud, B., Valerio, M., Rakauskas, A., Marra, G., Gontero, P., Porpiglia, F., Guo, H., Zhuang, J., Gandaglia, G., Montorsi, F., & Briganti, A. (2024). The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology. World Journal of Urology. https://doi.org/10.1007/s00345-024-04963-w

Vancouver

Sorce G, Stabile A, Pellegrino F, Mazzone E, Mattei A, Afferi L, et al. The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology. World Journal of Urology. 2024. doi:10.1007/s00345-024-04963-w

BibTeX
@article{Sorce2024,
  author = {Sorce, G and Stabile, A and Pellegrino, F and Mazzone, E and Mattei, A and Afferi, L and Serni, S and Minervini, A and Roumiguiè, M and Malavaud, B and Valerio, M and Rakauskas, A and Marra, G and Gontero, P and Porpiglia, F and Guo, H and Zhuang, J and Gandaglia, G and Montorsi, F and Briganti, A},
  title = {The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology},
  journal = {World Journal of Urology},
  year = {2024},
  doi = {10.1007/s00345-024-04963-w}
}
Kostenlos starten →